Ciprofloxacin (oral)

Jump to navigation Jump to search

Ciprofloxacin (oral)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
See full prescribing information for complete Boxed Warning.
* Fluoroquinolones, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart, or lung transplants.
  • Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis.

Overview

Ciprofloxacin (oral) is an antibiotic that is FDA approved for the treatment of urinary tract infections, chronic bacterial prostatitis, acute sinusitis, bone and joint infections, infectious diarrhea, typhoid fever. There is a Black Box Warning for this drug as shown here. Common adverse reactions include rash, diarrhea, headache, cardiorespiratory arrest, photosensitivity, agranulocytosis, hepatic necrosis, tendinitis, raised intracranial pressure, retinal detachment, depression, and acute renal failure.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. [1][2][3]

[4]

Adult Patients
Typhoid Fever (Enteric Fever) caused by Salmonella typhi
  • The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated.
  • Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae.
Pediatric Patients (1 to 17 years of age)
  • Complicated urinary tract infections and Pyelonephritis due to Escherichia coli.
  • Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues.
  • Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.
Adult and Pediatric Patients
  • Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
  • Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.
  • If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued.
  • As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and ciprofloxacin oral suspension and other antibacterial drugs, ciprofloxacin tablets and ciprofloxacin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
  • When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
  • The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function and hepatic function.
  • The duration of treatment depends upon the severity of infection. The usual duration is 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required. Ciprofloxacin should be administered at least 2 hours before or 6 hours after magnesium/aluminum antacids, polymeric phosphate binders (for example, sevelamer, lanthanum carbonate) or sucralfate, Videx® (didanosine) chewable/buffered tablets or pediatric powder for oral solution, other highly buffered drugs, or other products containing calcium, iron or zinc.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
Conversion of IV to Oral Dosing in Adults
  • Patients whose therapy is started with ciprofloxacin IV may be switched to ciprofloxacin Tablets or Oral Suspension when clinically indicated at the discretion of the physician.
This image is provided by the National Library of Medicine.
Adults with Impaired Renal Function
  • Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment.
  • Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction.
  • The following table provides dosage guidelines for use in patients with renal impairment:
This image is provided by the National Library of Medicine.
  • When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.
This image is provided by the National Library of Medicine.
  • The serum creatinine should represent a steady state of renal function.
  • In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patients should be carefully monitored.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

  • Safety and efficacy of extended-release ciprofloxacin (Cipro(R) XR) have not been established for treatment of infections other than UTIs.
  • Immediate-release and extended-release oral dosage forms are not interchangeable.
  • Patients initiated on ciprofloxacin IV therapy may be switched to oral ciprofloxacin when clinically indicated.
  • A desensitization schedule for ciprofloxacin hypersensitivity has been developed by 1 institution.
  • Bacteremia associated with intravascular line: (due to Ochrobacterium anthropi) 400 mg IV every 12 hours [5]
  • Bacterial meningitis: 800 to 1200 mg/day IV in divided doses every 8 to 12 hours [6]
  • Bacterial prostatitis, chronic: mild/moderate, 500 mg ORALLY every 12 hours for 28 days.
  • Bacterial prostatitis, chronic: mild/moderate, 400 mg IV every 12 hours for 28 days.
  • Bacterial sinusitis, acute: mild to moderate, 400 mg IV every 12 hours for 10 days.
  • Bacterial sinusitis, acute: mild to moderate, 500 mg ORALLY every 12 hours for 10 days.
  • Bronchitis, chronic, acute exacerbations: mild/moderate, 400 mg IV every 12 hours for 7 to 14 days.
  • Bronchitis, chronic, acute exacerbations: mild/moderate, 500 mg ORALLY every 12 hours for 7 to 14 days.
  • Bronchitis, chronic, acute exacerbations: severe/complicated, 400 mg IV every 8 hours for 7 to 14 days.
  • Bronchitis, chronic, acute exacerbations: severe/complicated, 750 mg ORALLY every 12 hours for 7 to 14 days.
  • Chancroid: 500 mg ORALLY twice a day for 3 days.
  • Febrile neutropenia, Empiric therapy: 400 mg IV every 8 hours for 7 to 14 days, in combination with piperacillin 50 mg/kg IV every 4 hours (maximum 24 g/day) [2]
  • Gonorrhea, Uncomplicated: 250 mg ORALLY as a single dose [6]; fluoroquinolones are no longer recommended by the CDC in the United States for the treatment of gonorrhea.
  • Granuloma inguinale: 750 mg ORALLY twice daily for at least 21 days and lesions are healed completely.[7]
  • HIV infection - Salmonella gastroenteritis: (mild disease with or without symptomatic bacteremia) 500 to 750 mg ORALLY twice daily or 400 mg IV twice daily; duration of 7 to 14 days if CD4+ count is at least 200/mcL, 2 to 6 weeks if CD4+ count is less than 200/mcL, or at least 6 months for recurrent symptomatic septicemia[8]
  • Infection of bone - Infectious disorder of joint: mild/moderate, 400 mg IV every 12 hours for at least 4 to 6 weeks.
  • Infection of bone - Infectious disorder of joint: mild/moderate, 500 mg ORALLY every 12 hours for at least 4 to 6 weeks.
  • Infection of bone - Infectious disorder of joint: severe/complicated, 400 mg IV every 8 hours for at least 4 to 6 weeks.
  • Infection of bone - Infectious disorder of joint: severe/complicated, 750 mg ORALLY every 12 hours for at least 4 to 6 weeks.
  • Infection of skin AND/OR subcutaneous tissue: mild/moderate, 400 mg IV every 12 hours for 7 to 14 days.
  • Infection of skin AND/OR subcutaneous tissue: mild/moderate, 500 mg ORALLY every 12 hours for 7 to 14 days.
  • Infection of skin AND/OR subcutaneous tissue: severe/complicated, 400 mg IV every 8 hours for 7 to 14 days.
  • Infection of skin AND/OR subcutaneous tissue: severe/complicated, 750 mg ORALLY every 12 hours for 7 to 14 days.
  • Infectious diarrheal disease: 500 mg orally every 12 hours for 5 to 7 days [6]
  • Infectious disease of abdomen, Complicated: 400 mg IV every 12 hours for 7 to 14 days, in combination with metronidazole.
  • Infectious disease of abdomen, Complicated: 500 mg ORALLY every 12 hours for 7 to 14 days, in combination with metronidazole.
  • Infective endocarditis: (native valve, culture-negative) 500 mg ORALLY or 400 mg IV every 12 hours, in combination with vancomycin 15 mg/kg IV every 12 hours AND gentamicin sulfate 1 mg/kg IV/IM every 8 hours, for 4 to 6 weeks [9][10]
  • Infective endocarditis: (prosthetic valve (late, greater than 1 year), culture-negative) 500 mg ORALLY or 400 mg IV every 12 hours, in combination with vancomycin 15 mg/kg IV every 12 hours AND gentamicin sulfate 1 mg/kg IV/IM every 8 hours, for 4 to 6 weeks AND rifampin 300 mg IV or ORALLY every 8 hours for 6 weeks.
  • Infective endocarditis: (native and prosthetic valve endocarditis caused by HACEK microorganisms) 500 mg ORALLY or 400 mg IV every 12 hours for 4 to 6 weeks[9]
  • Inhalational anthrax, Postexposure; Prophylaxis: 400 mg IV every 12 hours for 60 days.
  • Inhalational anthrax, Postexposure; Prophylaxis: 500 mg ORALLY every 12 hours for 60 days.
  • Lower respiratory tract infection: mild/moderate, 400 mg IV every 12 hours for 7 to 14 days.
  • Lower respiratory tract infection: mild/moderate, 500 mg ORALLY every 12 hours for 7 to 14 days.
  • Lower respiratory tract infection: severe/complicated, 400 mg IV every 8 hours for 7 to 14 days.
  • Lower respiratory tract infection: severe/complicated, 750 mg ORALLY every 12 hours for 7 to 14 days.
  • Nosocomial pneumonia: 400 mg IV every 8 hours for 10 to 14 days.
  • Pyelonephritis, acute, Uncomplicated: extended-release tablets (Cipro(R) XR), 1000 mg ORALLY once daily for 7 to 14 days [1]; clinical guidelines recommend a duration of 7 days for acute pyelonephritis[10]
  • Typhoid fever: 500 mg orally every 12 hours for 10 days.
  • Urinary tract infectious disease, Severe or complicated: 400 mg IV every 8 to 12 hours for 7 to 14 days.
  • Urinary tract infectious disease, Severe or complicated: immediate-release oral suspension, 500 mg ORALLY every 12 hours for 7 to 14 days.
  • Urinary tract infectious disease, Severe or complicated: extended-release tablets (Cipro(R) XR), 1000 mg ORALLY once daily for 7 to 14 days.
  • Urinary tract infectious disease, Uncomplicated: mild to moderate, 200 mg IV every 12 hours for 7 to 14 days.
  • Urinary tract infectious disease, Uncomplicated: acute cystitis (oral suspension), 250 mg ORALLY every 12 hours for 3 days.
  • Urinary tract infectious disease, Uncomplicated: mild/moderate (oral suspension), 250 mg ORALLY every 12 hours for 7 to 14 days.
  • Urinary tract infectious disease, Uncomplicated: acute cystitis (extended-release tablets Cipro(R) XR), 500 mg ORALLY once daily for 3 days.

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Ciprofloxacin tablets and oral suspension should be administered orally as described in the DOSAGE GUIDELINES TABLE. An increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues, has been observed.
This image is provided by the National Library of Medicine.
  • Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of complicated urinary tract infection and pyelonephritis.
  • No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (that is, creatinine clearance of < 50 mL/min/1.73m2).

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ciprofloxacin (oral) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ciprofloxacin (oral) in pediatric patients.

Contraindications

  • Ciprofloxacin is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antimicrobial agents, or any of the product components.
  • Concomitant administration with tizanidine is contraindicated.

Warnings

WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
See full prescribing information for complete Boxed Warning.
* Fluoroquinolones, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart, or lung transplants.
  • Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis.
Tendinopathy and Tendon Rupture
  • Fluoroquinolones, including CIPRO, are associated with an increased risk of tendinitis and tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair.
  • Tendinitis and tendon rupture in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported.
  • The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
  • Factors, in addition to age and corticosteroid use, that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.
  • Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who do not have the above risk factors. Inflammation and tendon rupture can occur, sometimes bilaterally, even within the first 48 hours, during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported.
  • CIPRO should be used with caution in patients with a history of tendon disorders. CIPRO should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug.
Exacerbation of Myasthenia Gravis
  • Fluoroquinolones, including CIPRO, have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.
  • Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with myasthenia gravis. Avoid CIPRO in patients with known history of myasthenia gravis.
Pregnant Women
  • THE SAFETY AND EFFECTIVENESS OF CIPROFLOXACIN IN PREGNANT AND LACTATING WOMEN HAVE NOT BEEN ESTABLISHED.
Hypersensitivity Reactions
  • Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine.
  • Oxygen, intravenous steroids, and airway management, including intubation, should be administered as indicated.
Other Serious and Sometimes Fatal Reactions
Hepatobiliary System
  • Cases of severe hepatotoxicity, includinghepatic necrosis, life-threatening hepatic failure, and fatal events,have been reported with ciprofloxacin.
  • Acute liver injury is rapid in onset (range 1-39 days), and is often associated with hypersensitivity. The pattern of injury can be hepatocellular, cholestatic or mixed.
  • Most patients with fatal outcomes were older than 55 years old. In the event of any signs and symptoms of hepatitis (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued immediately.
  • There can be a temporary increase in transaminases, alkaline phosphatase, or cholestatic jaundice, especially in patients with previous liver damage, who are treated with ciprofloxacin.
Theophylline
  • SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVINGCONCURRENT ADMINISTRATION OF CIPROFLOXACIN AND THEOPHYLLINE. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure.
  • Although similar serious adverse effects have been reported in patients receiving theophylline alone, the possibility that these reactions may be potentiated by ciprofloxacin cannot be eliminated. If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
Central Nervous System Effects
  • Convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis have been reported in patients receiving fluoroquinolones, including ciprofloxacin. Ciprofloxacin may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression, and, rarely, psychotic reactions have progressed to suicidal ideations/thoughts and self-injurious behavior such as attempted or completed suicide. These reactions may occur following the first dose.
  • If these reactions occur in patients receiving ciprofloxacin, the drug should be discontinued, patients should be advised to inform their healthcare provider immediately and appropriate measures instituted. Cipro, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold.
  • As with all fluoroquinolones, ciprofloxacin should be used with caution in epileptic patients and patients with known or suspected CNS disorders that may predispose to seizures or lower the seizure threshold (for example, severe cerebral arteriosclerosis, previous history of convulsion, reduced cerebral blood flow, altered brain structure, or stroke), or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (for example, certain drug therapy, renal dysfunction).
  • CIPRO should only be used where the benefits of treatment exceed the risks, since these patients are endangered because of possible undesirable CNS side effects. Cases of status epilepticus have been reported. If seizures occur, ciprofloxacin should be discontinued.
Clostridium Difficile-Associated Diarrhea
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CIPRO, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
  • C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficilecause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
  • CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
  • If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficilemay need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Peripheral Neuropathy
  • Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving quinolones, including ciprofloxacin.
  • Ciprofloxacin should be discontinued if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness, or is found to have deficits in light touch, pain, temperature, position sense, vibratory sensation, and/or motor strength in order to prevent the development of an irreversible condition.
  • Patients treated with CIPRO should be advised to inform their healthcare provider prior to continuing treatment if symptoms of neuropathy develop.
  • Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals
  • An increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues, has been observed.
  • In pre-clinical studies, oral administration of ciprofloxacin caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species.
Prolongation of the QT Interval
  • Some fluoroquinolones, including ciprofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia.
  • Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including ciprofloxacin.
  • Ciprofloxacin should be avoided in patients with known prolongation of the QT interval, risk factors for QT prolongation or torsade de pointes (for example, congenital long QT syndrome , uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhthmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics.
  • Elderly patients may also be more susceptible to drug-associated effects on the QT interval.
Cytochrome P450 (CYP450) Drug Interactions
  • Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme pathway. Coadministration of ciprofloxacin and other drugs primarily metabolized by CYP1A2 (for example, theophylline, methylxanthines, caffeine, tizanidine, ropinirole, clozapine, olanzapine) results in increased plasma concentrations of the coadministered drug and could lead to clinically significant pharmacodynamic side effects of the coadministered drug.
Syphilis
  • Ciprofloxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high dose for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis.
  • All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with ciprofloxacin should have a follow-up serologic test for syphilis after three months.

Adverse Reactions

Clinical Trials Experience

Adverse Reactions in Adult Patients
  • During clinical investigations with oral and parenteral ciprofloxacin, 49,038 patients received courses of the drug. Most of the adverse events reported were described as only mild or moderate in severity, abated soon after the drug was discontinued, and required no treatment.
  • Ciprofloxacin was discontinued because of an adverse event in 1% of orally treated patients.
  • The most frequently reported drug related events, from clinical trials of all formulations, all dosages, all drug-therapy durations, and for all indications of ciprofloxacin therapy were nausea (2.5%), diarrhea (1.6%), liver function tests abnormal (1.3%), vomiting (1%), and rash (1%).
  • Additional medically important events that occurred in less than 1% of ciprofloxacin patients are listed below.
  • BODY AS A WHOLE: headache, abdominal pain/discomfort, foot pain, pain, pain in extremities, injection site reaction (ciprofloxacin intravenous)
  • CARDIOVASCULAR: palpitation, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phlebitis, tachycardia, migraine, hypotension
  • CENTRAL NERVOUS SYSTEM: restlessness, dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures (including status epilepticus), grand mal convulsion, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression (potentially culminating in self-injurious behavior, such as suicidal ideations/thoughts and attempted or completed suicide), paresthesia, abnormal gait
  • GASTROINTESTINAL: painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding, cholestatic jaundice, hepatitis
  • HEMIC/LYMPHATIC: lymphadenopathy, petechia
  • METABOLIC/NUTRITIONAL: amylase increase, lipase increase, hyperglycemia, hypoglycemia
  • MUSCULOSKELETAL: arthralgia or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout, muscle weakness
  • RENAL/UROGENITAL: interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain
  • RESPIRATORY: dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough, hemoptysis, bronchospasm, pulmonary embolism
  • SKIN/HYPERSENSITIVITY: allergic reaction, pruritus, urticaria, photosensitivity/phototoxicity reaction, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema nodosum, sweating
  • SPECIAL SENSES: blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia
  • In several instances nausea, vomiting, tremor, irritability, or palpitation were judged by investigators to be related to elevated serum levels of theophylline possibly as a result of drug interaction with ciprofloxacin.
  • In randomized, double-blind controlled clinical trials comparing ciprofloxacin tablets (500 mg BID) to cefuroxime axetil (250 mg - 500 mg BID) and to clarithromycin (500 mg BID) in patients with respiratory tract infections, ciprofloxacin demonstrated a CNS adverse event profile comparable to the control drugs.
Adverse Reactions in Pediatric Patients
  • Ciprofloxacin, administered IV and /or orally, was compared to a cephalosporin for treatment of complicated urinary tract infections (cUTI) or pyelonephritis in pediatric patients 1 to 17 years of age (mean age of 6 ± 4 years). The trial was conducted in the US, Canada, Argentina, Peru, Costa Rica, Mexico, South Africa, and Germany. The duration of therapy was 10 to 21 days (mean duration of treatment was 11 days with a range of 1 to 88 days). The primary objective of the study was to assess musculoskeletal and neurological safety within 6 weeks of therapy and through one year of follow-up in the 335 ciprofloxacin- and 349 comparator-treated patients enrolled.
  • An Independent Pediatric Safety Committee (IPSC) reviewed all cases of musculoskeletal adverse events as well as all patients with an abnormal gait or abnormal joint exam (baseline or treatment-emergent). These events were evaluated in a comprehensive fashion and included such conditions as arthralgia, abnormal gait, abnormal joint exam, joint sprains, leg pain, back pain, arthrosis, bone pain, pain, myalgia, arm pain, and decreased range of motion in a joint. The affected joints included: knee, elbow, ankle, hip, wrist, and shoulder. Within 6 weeks of treatment initiation, the rates of these events were 9.3% (31/335) in the ciprofloxacin-treated group versus 6 % (21/349) in comparator-treated patients.
  • The majority of these events were mild or moderate in intensity. All musculoskeletal events occurring by 6 weeks resolved (clinical resolution of signs and symptoms), usually within 30 days of end of treatment. Radiological evaluations were not routinely used to confirm resolution of the events.
  • The events occurred more frequently in ciprofloxacin-treated patients than control patients, regardless of whether they received IV or oral therapy. Ciprofloxacin-treated patients were more likely to report more than one event and on more than one occasion compared to control patients. These events occurred in all age groups and the rates were consistently higher in the ciprofloxacin group compared to the control group. At the end of 1 year, the rate of these events reported at any time during that period was 13.7% (46/335) in the ciprofloxacin-treated group versus 9.5% (33/349) comparator-treated patients.
  • An adolescent female discontinued ciprofloxacin for wrist pain that developed during treatment. An MRI performed 4 weeks later showed a tear in the right ulnar fibrocartilage. A diagnosis of overuse syndrome secondary to sports activity was made, but a contribution from ciprofloxacin cannot be excluded. The patient recovered by 4 months without surgical intervention.
This image is provided by the National Library of Medicine.
  • The incidence rates of neurological events within 6 weeks of treatment initiation were 3% (9/335) in the ciprofloxacin group versus 2% (7/349) in the comparator group and included dizziness, nervousness, insomnia, and somnolence.
  • In this trial, the overall incidence rates of adverse events regardless of relationship to study drug and within 6 weeks of treatment initiation were 41% (138/335) in the ciprofloxacin group versus 31% (109/349) in the comparator group. The most frequent events were gastrointestinal: 15% (50/335) of ciprofloxacin patients compared to 9% (31/349) of comparator patients. Serious adverse events were seen in 7.5% (25/335) of ciprofloxacin-treated patients compared to 5.7% (20/349) of control patients.
  • Discontinuation of drug due to an adverse event was observed in 3% (10/335) of ciprofloxacin-treated patients versus 1.4% (5/349) of comparator patients. Other adverse events that occurred in at least 1% of ciprofloxacin patients were diarrhea 4.8%, vomiting 4.8%, abdominal pain 3.3%, accidental injury 3%, rhinitis 3%, dyspepsia 2.7%, nausea 2.7%, fever 2.1%, asthma 1.8% and rash 1.8%.
  • In addition to the events reported in pediatric patients in clinical trials, it should be expected that events reported in adults during clinical trials or postmarketing experience may also occur in pediatric patients.

Postmarketing Experience

This image is provided by the National Library of Medicine.
  • Other changes occurring in less than 0.1% of courses were: elevation of serum gammaglutamyl transferase, elevation of serum amylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, anemia, bleeding diathesis, increase in blood monocytes, and leukocytosis.

Drug Interactions

  • When CIPRO Tablet is given concomitantly with food, there is a delay in the absorption of the drug, resulting in peak concentrations that occur closer to 2 hours after dosing rather than 1 hour whereas there is no delay observed when CIPRO Suspension is given with food.
  • The overall absorption of CIPRO Tablet or CIPRO Suspension, however, is not substantially affected. The pharmacokinetics of ciprofloxacin given as the suspension are also not affected by food. Concurrent administration of antacids containing magnesium hydroxide or aluminum hydroxide may reduce the bioavailability of ciprofloxacin by as much as 90%.
  • The serum concentrations of ciprofloxacin and metronidazole were not altered when these two drugs were given concomitantly.
  • Concomitant administration with tizanidine is contraindicated. Concomitant administration of ciprofloxacin with theophylline decreases the clearance of theophylline resulting in elevated serum theophylline levels and increased risk of a patient developing CNS or other adverse reactions.
  • Ciprofloxacin also decreases caffeine clearance and inhibits the formation of paraxanthine after caffeine administration.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Pregnancy Category


Pregnancy Category (AUS): B3

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ciprofloxacin (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ciprofloxacin (oral) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ciprofloxacin (oral) with respect to nursing mothers.

Pediatric Use

  • Following a single oral dose of 10 mg/kg ciprofloxacin suspension to 16 children ranging in age from 4 months to 7 years, the mean Cmax was 2.4 mcg/mL (range: 1.5 – 3.4 mcg/mL) and the mean AUC was 9.2 mcg*h/mL (range: 5.8 – 14.9 mcg*h/mL). There was no apparent age-dependence, and no notable increase in Cmax or AUC upon multiple dosing (10 mg/kg TID).
  • In children with severe sepsis who were given intravenous ciprofloxacin (10 mg/kg as a 1-hour infusion), the mean Cmax was 6.1 mcg/mL (range: 4.6 – 8.3 mcg/mL) in 10 children less than 1 year of age; and 7.2 mcg/mL (range: 4.7 – 11.8 mcg/mL) in 10 children between 1 and 5 years of age. The AUC values were 17.4 mcg*h/mL (range: 11.8 – 32 mcg*h/mL) and 16.5 mcg*h/mL (range: 11 – 23.8 mcg*h/mL) in the respective age groups. These values are within the range reported for adults at therapeutic doses.
  • Based on population pharmacokinetic analysis of pediatric patients with various infections, the predicted mean half-life in children is approximately 4 - 5 hours, and the bioavailability of the oral suspension is approximately 60%.

Geriatic Use

There is no FDA guidance on the use of Ciprofloxacin (oral) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ciprofloxacin (oral) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ciprofloxacin (oral) with respect to specific racial populations.

Renal Impairment

  • In patients with reduced renal function, the half-life of ciprofloxacin is slightly prolonged. Dosage adjustments may be required.

Hepatic Impairment

  • In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been fully elucidated.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ciprofloxacin (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ciprofloxacin (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

  • If concomitant use of theophylline, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
  • In some older individuals experience reduced renal function by virtue of their advanced age, care should be taken in dose selection for elderly patients, and renal function monitoring may be useful in these patients.

IV Compatibility

There is limited information regarding IV Compatibility of Ciprofloxacin (oral) in the drug label.

Overdosage

  • In the event of acute overdosage, reversible renal toxicity has been reported in some cases. The stomach should be emptied by inducing vomiting or by gastric lavage.
  • The patient should be carefully observed and given supportive treatment, including monitoring of renal function, urinary pH and acidify, if required, to prevent crystalluria and administration of magnesium, aluminum, or calcium containing antacids which can reduce the absorption of ciprofloxacin.
  • Adequate hydration must be maintained. Only a small amount of ciprofloxacin (< 10%) is removed from the body after hemodialysis or peritoneal dialysis.
  • Single doses of ciprofloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post treatment observation period at the highest oral doses tested; up to 5000 mg/kg in either rodent species, or up to 2500 mg/kg in the dog.
  • Clinical signs observed included hypoactivity and cyanosis in both rodent species and severe vomiting in dogs. In rabbits, significant mortality was Seen at doses of ciprofloxacin > 2500 mg/kg. Mortality was delayed in these animals, occurring 10-14 days after dosing.
  • In mice, rats, rabbits and dogs, significant toxicity including tonic/clonic convulsions was observed at intravenous doses of ciprofloxacin between 125 and 300 mg/kg.

Pharmacology

Template:Px
Template:Px
Ciprofloxacin (oral)
Systematic (IUPAC) name
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid
Identifiers
CAS number 85721-33-1
ATC code J01MA02 S01AE03 (WHO) S02AA15 (WHO) S03AA07 (WHO)
PubChem 2764
DrugBank DB00537
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 331.346 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 69%[11]
Metabolism Hepatic, including CYP1A2
Half life 4 hours
Excretion Renal
Therapeutic considerations
Licence data

US

Pregnancy cat.

B3(AU) C(US)

Legal status

Prescription Only (S4)(AU) POM(UK) [[Prescription drug|Template:Unicode-only]](US)

Routes Oral, intravenous, topical (ear drops, eye drops)

Mechanism of Action

  • Ciprofloxacin is a broad-spectrum antibiotic active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV,[12]enzymes [13] necessary to separate bacterial DNA, thereby inhibiting cell division.

Structure

  • CIPRO (ciprofloxacin hydrochloride) Tablets and CIPRO (ciprofloxacin*) Oral Suspension are synthetic broad spectrum antimicrobial agents for oral administration.
  • Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is a faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its empirical formula is C17H18FN3O3•HCl•H2O and its chemical structure is as follows:
This image is provided by the National Library of Medicine.
  • Ciprofloxacin is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C17H18FN3O3 and its molecular weight is 331.4. It is a faintly yellowish to light yellow crystalline substance and its chemical structure is as follows:
This image is provided by the National Library of Medicine.
  • CIPRO film-coated tablets are available in 250 mg and 500 mg (ciprofloxacin equivalent) strengths. Ciprofloxacin tablets are white to slightly yellowish. The inactive ingredients are cornstarch, microcrystalline cellulose, silicon dioxide, crospovidone, magnesium stearate, hypromellose, titanium dioxide, and polyethylene glycol.
  • Ciprofloxacin Oral Suspension is available in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. Ciprofloxacin Oral Suspension is a white to slightly yellowish suspension with strawberry flavor which may contain yellow-orange droplets. It is composed of ciprofloxacin microcapsules and diluent which are mixed prior to dispensing. The components of the suspension have the following compositions:
  • Microcapsules – ciprofloxacin, povidone, methacrylic acid copolymer, hypromellose, magnesium stearate, and Polysorbate 20.
  • Diluent – medium-chain triglycerides, sucrose, lecithin, water, and strawberry flavor.
  • Five (5) mL of 5% suspension contains approximately 1.4 g of sucrose and 5 mL of 10% suspension contains approximately 1.3 g of sucrose.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ciprofloxacin (oral) in the drug label.

Pharmacokinetics

Absorption
  • Ciprofloxacin given as an oral tablet is rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism. Ciprofloxacin maximum serum concentrations and area under the curve are shown in the chart for the 250 mg to 1000 mg dose range.[14]
This image is provided by the National Library of Medicine.
  • Maximum serum concentrations are attained 1 to 2 hours after oral dosing. Mean concentrations 12 hours after dosing with 250, 500, or 750 mg are 0.1, 0.2, and 0.4 mcg/mL, respectively. The serum elimination half-life in subjects with normal renal function is approximately 4 hours.
  • Serum concentrations increase proportionately with doses up to 1000 mg.
  • A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.
  • A 750 mg oral dose given every 12 hours has been shown to produce an AUC at steady-state equivalent to that produced by an intravenous infusion of 400 mg given over 60 minutes every 8 hours. * A 750 mg oral dose results in a Cmax similar to that observed with a 400 mg IV dose. A 250 mg oral dose given every 12 hours produces an AUC equivalent to that produced by an infusion of 200 mg ciprofloxacin given every 12 hours.
This image is provided by the National Library of Medicine.
Distribution
  • The binding of ciprofloxacin to serum proteins is 20 to 40% which is not likely to be high enough to cause significant protein binding interactions with other drugs.
  • After oral administration, ciprofloxacin is widely distributed throughout the body. Tissue concentrations often exceed serum concentrations in both men and women, particularly in genital tissue including the prostate. Ciprofloxacin is present in active form in the saliva, nasal and bronchial secretions, mucosa of the sinuses, sputum, skin blister fluid, lymph, peritoneal fluid, bile, and prostatic secretions.
  • Ciprofloxacin has also been detected in lung, skin, fat, muscle, cartilage, and bone. The drug diffuses into the cerebrospinal fluid (CSF); however, CSF concentrations are generally less than 10% of peak serum concentrations. Low levels of the drug have been detected in the aqueous and vitreous humors of the eye.
Metabolism
  • Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.
  • Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Coadministration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the coadministered drug.
Excretion
  • The serum elimination half-life in subjects with normal renal function is approximately 4 hours.
  • Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. After a 250 mg oral dose, urine concentrations of ciprofloxacin usually exceed 200 mcg/mL during the first two hours and are approximately 30 mcg/mL at 8 to 12 hours after dosing.
  • The urinary excretion of ciprofloxacin is virtually complete within 24 hours after dosing. The renal clearance of ciprofloxacin, which is approximately 300 mL/minute, exceeds the normal glomerular filtration rate of 120 mL/minute. Thus, active tubular secretion would seem to play a significant role in its elimination. Co-administration of probenecid with ciprofloxacin results in about a 50% reduction in the ciprofloxacin renal clearance and a 50% increase in its concentration in the systemic circulation. Although bile concentrations of ciprofloxacin are several fold higher than serum concentrations after oral dosing, only a small amount of the dose administered is recovered from the bile as unchanged drug. An additional 1 to 2% of the dose is recovered from the bile in the form of metabolites.
  • Approximately 20 to 35% of an oral dose is recovered from the feces within 5 days after dosing. This may arise from either biliary clearance or transintestinal elimination.
  • With oral administration, a 500 mg dose, given as 10 mL of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to the 500 mg tablet. A 10 mL volume of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to a 5 mL volume of the 10% CIPRO Suspension (containing 500 mg ciprofloxacin/5mL).

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ciprofloxacin (oral) in the drug label.

Clinical Studies

Complicated Urinary Tract Infection and Pyelonephritis – Efficacy in Pediatric Patients
  • NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues.
  • Ciprofloxacin, administered IV and/or orally, was compared to a cephalosporin for treatment of complicated urinary tract infections (cUTI) and pyelonephritis in pediatric patients 1 to 17 years of age (mean age of 6 ± 4 years). The trial was conducted in the US, Canada, Argentina, Peru, Costa Rica, Mexico, South Africa, and Germany. The duration of therapy was 10 to 21 days (mean duration of treatment was 11 days with a range of 1 to 88 days). The primary objective of the study was to assess musculoskeletal and neurological safety.
  • Patients were evaluated for clinical success and bacteriological eradication of the baseline organism(s) with no new infection or superinfection at 5 to 9 days post-therapy (Test of Cure or TOC). The Per Protocol population had a causative organism(s) with protocol specified colony count(s) at baseline, no protocol violation, and no premature discontinuation or loss to follow-up (among other criteria).
  • The clinical success and bacteriologic eradication rates in the Per Protocol population were similar between ciprofloxacin and the comparator group as shown below.
This image is provided by the National Library of Medicine.
Inhalational Anthrax In Adults And Pediatrics
Additional Information
  • The mean serum concentrations of ciprofloxacin associated with a statistically significant improvement in survival in the rhesus monkey model of inhalational anthrax are reached or exceeded in adult and pediatric patients receiving oral and intravenous regimens.
  • Ciprofloxacin pharmacokinetics have been evaluated in various human populations. The mean peak serum concentration achieved at steady-state in human adults receiving 500 mg orally every 12 hours is 2.97 mcg/mL, and 4.56 mcg/mL following 400 mg intravenously every 12 hours.
  • The mean trough serum concentration at steady-state for both of these regimens is 0.2 mcg/mL. In a study of 10 pediatric patients between 6 and 16 years of age, the mean peak plasma concentration achieved is 8.3 mcg/mL and trough concentrations range from 0.09 to 0.26 mcg/mL, following two 30-minute intravenous infusions of 10 mg/kg administered 12 hours apart.
  • After the second intravenous infusion patients switched to 15 mg/kg orally every 12 hours achieve a mean peak concentration of 3.6 mcg/mL after the initial oral dose. Long-term safety data, including effects on cartilage, following the administration of ciprofloxacin to pediatric patients are limited.
  • Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication.
  • A placebo-controlled animal study in rhesus monkeys exposed to an inhaled mean dose of 11 LD50 (~5.5 x 105 spores (range 5-30 LD50) of B. anthracis was conducted.
  • The minimal inhibitory concentration (MIC) of ciprofloxacin for the anthrax strain used in this study was 0.08 mcg/mL. In the animals studied, mean serum concentrations of ciprofloxacin achieved at expected Tmax (1 hour post-dose) following oral dosing to steady-state ranged from 0.98 to 1.69 mcg/mL.
  • Mean steady-state trough concentrations at 12 hours post-dose ranged from 0.12 to 0.19 mcg/mL.7 Mortality due to anthrax for animals that received a 30-day regimen of oral ciprofloxacin beginning 24 hours post-exposure was significantly lower (1/9), compared to the placebo group (9/10) [p= 0.001].
  • The one ciprofloxacin-treated animal that died of anthrax did so following the 30-day drug administration period.
  • More than 9300 persons were recommended to complete a minimum of 60 days of antibiotic prophylaxis against possible inhalational exposure to B. anthracis during 2001.
  • Ciprofloxacin was recommended to most of those individuals for all or part of the prophylaxis regimen. Some persons were also given anthrax vaccine or were switched to alternative antibiotics. No one who received ciprofloxacin or other therapies as prophylactic treatment subsequently developed inhalational anthrax. * The number of persons who received ciprofloxacin as all or part of their post-exposure prophylaxis regimen is unknown.
  • Among the persons surveyed by the Centers for Disease Control and Prevention, over 1000 reported receiving ciprofloxacin as sole post-exposure prophylaxis for inhalational anthrax.
  • Gastrointestinal adverse events (nausea, vomiting, diarrhea, or stomach pain), neurological adverse events (problems sleeping, nightmares, headache, dizziness or lightheadedness) and musculoskeletal adverse events (muscle or tendon pain and joint swelling or pain) were more frequent than had been previously reported in controlled clinical trials.
  • This higher incidence, in the absence of a control group, could be explained by a reporting bias, concurrent medical conditions, other concomitant medications, emotional stress or other confounding factors, and/or a longer treatment period with ciprofloxacin. Because of these factors and limitations in the data collection, it is difficult to evaluate whether the reported symptoms were drug-related.
  • Instructions To The Pharmacist For Use/Handling Of CIPRO Oral Suspension:
  • CIPRO Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. The drug product is composed of two components (microcapsules and diluent) which must be combined prior to dispensing.
  • One teaspoonful (5 mL) of 5% ciprofloxacin oral suspension = 250 mg of ciprofloxacin.
  • One teaspoonful (5 mL) of 10% ciprofloxacin oral suspension = 500 mg of ciprofloxacin.

How Supplied

  • CIPRO (ciprofloxacin hydrochloride) Tablets are available as round, slightly yellowish film-coated tablets containing 250 mg ciprofloxacin. The 250 mg tablet is coded with the word “BAYER” on one side and “CIP 250” on the reverse side. CIPRO is also available as capsule shaped, slightly yellowish film-coated tablets containing 500 mg ciprofloxacin. The 500 mg tablet is coded with the word “BAYER” on one side and “CIP 500” on the reverse side. CIPRO 250 mg and 500 mg are available in bottles of 100.
This image is provided by the National Library of Medicine.
  • CIPRO Oral Suspension is supplied in 5% and 10% strengths. The drug product is composed of two components (microcapsules containing the active ingredient and diluent) which must be mixed by the pharmacist.
This image is provided by the National Library of Medicine.

Storage

  • Store below 30°C (86°F).
  • Microcapsules and diluent should be stored below 25°C (77°F) and protected from freezing.
  • Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing. A graduated teaspoon (5mL) with markings 1/2 and 1/1 is provided for the patient.

Images

Drug Images

{{#ask: Page Name::Ciprofloxacin (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.

{{#ask: Label Page::Ciprofloxacin (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

Instruct the patient
  • To shake CIPRO Oral Suspension vigorously each time before use for approximately 15 seconds
  • To always use the graduated measuring spoon to obtain the exact dose.
  • Not chew the microcapsules, but to swallow them.

That water may be taken afterwards.

  • Reclose the bottle properly after each use according to instructions on the cap.
  • After treatment has been completed, Cipro Oral Suspension should not be reused.

Precautions with Alcohol

  • Alcohol-Ciprofloxacin (oral) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Ciprofloxacin (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Adam MP, Polifka JE, Friedman JM (2011). "Evolving knowledge of the teratogenicity of medications in human pregnancy". Am J Med Genet C Semin Med Genet. 157C (3): 175–82. doi:10.1002/ajmg.c.30313. PMID 21766440.
  2. ↑ Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE; et al. (1998). "Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study". Antimicrob Agents Chemother. 42 (6): 1336–9. PMC 105599. PMID 9624471.
  3. ↑ Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E; et al. (1996). "Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)". Eur J Obstet Gynecol Reprod Biol. 69 (2): 83–9. PMID 8902438.
  4. ↑ Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ; et al. (1993). "Postexposure prophylaxis against experimental inhalation anthrax". J Infect Dis. 167 (5): 1239–43. PMID 8486963.
  5. ↑ Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP; et al. (2009). "Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America". Clin Infect Dis. 49 (1): 1–45. doi:10.1086/599376. PMC 4039170. PMID 19489710 PMID: 19489710 Check |pmid= value (help).
  6. ↑ Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM; et al. (2004). "Practice guidelines for the management of bacterial meningitis". Clin Infect Dis. 39 (9): 1267–84. doi:10.1086/425368. PMID 15494903.
  7. ↑ "The Centers for Disease Control and Prevention" (PDF).
  8. ↑ Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; et al. (2009). "Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America". MMWR Recomm Rep. 58 (RR-4): 1–207, quiz CE1-4. PMID 19357635.
  9. ↑ Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME; et al. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145 PMID: 15956145 Check |pmid= value (help).
  10. ↑ Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG; et al. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654 PMID: 21292654 Check |pmid= value (help).
  11. ↑ Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J, GL (September 1986). "Absolute oral bioavailability of ciprofloxacin". Antimicrob Agents Chemother. 30 (3): 444–6. doi:10.1128/aac.30.3.444. ISSN 0066-4804. PMC 180577. PMID 3777908. |first2= missing |last2= in Authors list (help); |first3= missing |last3= in Authors list (help); |first4= missing |last4= in Authors list (help); |first5= missing |last5= in Authors list (help); |first6= missing |last6= in Authors list (help)
  12. ↑ Li S, Luo J, Anwar S, Li S, Lu W, Hang ZH; et al. (2014). "An equivalent realization of coherent perfect absorption under single beam illumination". Sci Rep. 4: 7369. doi:10.1038/srep07369. PMID 25482592.
  13. ↑ "DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs".
  14. ↑ Kelly DJ, Chulay JD, Mikesell P, Friedlander AM (1992). "Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys". J Infect Dis. 166 (5): 1184–7. PMID 1402033.
  15. ↑ "CIPRO- ciprofloxacin hydrochloride tablet, film coated".

{{#subobject: 

 |Label Page=Ciprofloxacin (oral)
 |Label Name=444.jpg

}}

{{#subobject: 

 |Label Page=Ciprofloxacin (oral)
 |Label Name=222.jpg

}}

{{#subobject: 

 |Label Page=Ciprofloxacin (oral)
 |Label Name=Cipro1.jpg

}}

{{#subobject: 

 |Label Page=Ciprofloxacin (oral)
 |Label Name=333.jpg

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Ciprofloxacin_(oral)&oldid=1135024"